Vorasidenib
Brand names: Voranigo · Active ingredient: Vorasidenib
In short: VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery includin
What is Vorasidenib used for?
VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection .
Vorasidenib dosage
Before initiating VORANIGO, evaluate blood chemistry and liver laboratory tests .
Select patients with Grade 2 astrocytoma or oligodendroglioma for treatment with VORANIGO based on the presence of IDH1 or IDH2 mutations in tumor specimens .
Information on FDA-approved tests for detection of IDH1 or IDH2 mutations in Grade 2 astrocytoma or oligodendroglioma for selecting patients for treatment with VORANIGO is available at: https://www.fda.gov/CompanionDiagnostics.
Recommended Dosage
Adult Patients
The recommended dosage of VORANIGO in adult patients is 40 mg orally once daily until disease progression or unacceptable toxicity.
Pediatric Patients 12 Years and Older
The recommended dosage of VORANIGO in pediatric patients 12 years and older is based on body weight:
Patients weighing ≥40 kg: 40 mg orally once daily
Patients weighing <40 kg: 20 mg orally once daily
Continue treatment with VORANIGO until disease progression or unacceptable toxicity.
Administration
Swallow VORANIGO tablets whole with water with or without food . Do not split, crush or chew tablets.
Missed Dose
Take VORANIGO tablets at about the same time each day. If a dose is missed, take the missed dose as soon as possible within 6 hours. If a dose is missed by more than 6 hours, skip the missed dose and take the next dose at the scheduled time.
Vomiting
If vomiting occurs after taking a dose, do not take a replacement dose, and take the next dose at the scheduled time on the following day.
The recommended VORANIGO dosage reductions for adverse reactions are provided in Table 1.
Dosage Reduction | Recommended Dose and Schedule
Adult patients and Pediatric patients 12 years and older weighing at least 40 kg
First | 20 mg once daily
Second | 10 mg once daily
Pediatric patients 12 years and older weighing less than 40 kg
First | 10 mg once daily
Permanently discontinue VORANIGO in patients unable to tolerate 10 mg once daily.
The recommended management for adverse reactions and VORANIGO dosage modifications for adverse reactions are provided in Table 2.
Adverse Reaction | SeverityAdverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. | Management and Dosage Modifications
Abbreviations: ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; ULN = Upper limit of normal
Hepatotoxicity (Elevation of ALT or AST)
| Grade 1 ALT or AST increase >ULN to 3 × ULN without concurrent total bilirubin >2 × ULN | Continue VORANIGO at current dose. Monitor liver laboratory tests weekly until recovery to Grade < 1.
Grade 2 ALT or AST >3 to 5 × ULN without concurrent total bilirubin >2 × ULN | First Occurrence:Withhold VORANIGO until recovery to Grade ≤ 1 or baseline.
Recovery in ≤28 days, resume VORANIGO at the same dose. …
How to take Vorasidenib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hepatotoxicity
Inform patients of the risk of hepatotoxicity and to promptly report any signs or symptoms of hepatotoxicity to their healthcare provider .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy .
Advise females of reproductive potential to use effective nonhormonal contraception during treatment with VORANIGO and for 3 months after the last dose since VORANIGO can render some hormonal contraceptives ineffective .
Advise males with female partners of reproductive potential to use effective contraception during treatment with VORANIGO and for 3 months after the last dose .
Lactation
Advise women not to breastfeed during treatment with VORANIGO and for 2 months after the last dose .
Infertility
Advise females and males of reproductive potential that VORANIGO may impair fertility . …
Warnings & precautions
Do not take this medicine if: None.
VORANIGO can cause hepatic transaminase elevations, which can lead to hepatic failure, hepatic necrosis, and autoimmune hepatitis.
In the pooled safety population , 58% of patients treated with VORANIGO experienced increased ALT and 44% of patients experienced increased AST. Grade 3 or 4 increased ALT or AST occurred in 9% and 4.8% of patients respectively. Among these patients, 4.1% (10/244) had concurrent Grade 3 to 4 ALT or AST elevations. A total of 34% of patients treated with VORANIGO had increased gamma-glutamyl transferase (GGT), of these 2.2% were Grade 3 or 4. Bilirubin increases occurred in 4.8% of patients treated with VORANIGO, with 0.4% Grade 3 or 4. Nine percent of patients treated with VORANIGO had increased alkaline phosphatase, with 0.9% Grade 3 or 4.
Two patients met the laboratory criteria for Hy's Law and had concurrent elevations in ALT or AST >3 times the upper limit of normal and total bilirubin >2 times the upper limit of normal; these events were associated with cases of autoimmune hepatitis and hepatic failure. The median time to first onset of increased ALT or AST was 57 days (range: 1 to 1049).
Acute hepatitis occurred in the postmarketing setting.
Permanent discontinuation of VORANIGO was required for 2.9% of patients with ALT elevations, 1.6% of AST elevations, and 0.4% of GGT elevations. Dosage reductions of VORANIGO were required for 7% of patients with ALT elevations, 1.2% of AST elevations, and 0.4% of GGT elevations. Dosage interruptions were required in 14% of patients with ALT elevations, 6% of AST elevations, and 1.6% of GGT elevations. …
Vorasidenib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hepatotoxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions described in the WARNINGS AND PRECAUTIONS reflect exposure to VORANIGO 40 mg orally once daily until disease progression or unacceptable toxicity in the 244 patients with astrocytoma or oligodendroglioma with susceptible IDH1 or IDH2 mutation in trials AG881-C-002 (NCT02481154, n=11), AG120-881-001 (NCT03343197, n=14) and INDIGO (NCT04164901, n=167 randomized patients and n=52 crossover patients). Among the 244 patients who received VORANIGO, 78% were exposed for 6 months or longer and 44% were exposed for greater than one year. In this pooled safety population, the most common (≥15%) adverse reactions were fatigue (33%), headache (28%), COVID-19 (28%), musculoskeletal pain (24%), diarrhea (21%), nausea (20%), and seizure (16%). In this pooled safety population, the most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT (9%), increased AST (4.8%), increased GGT (2.2%), and decreased neutrophils (2.2%). …
Drug interactions
Strong and Moderate CYP1A2 Inhibitors
Clinical Impact | Concomitant use of VORANIGO with a strong or moderate CYP1A2 inhibitor may increase vorasidenib plasma concentrations , which may increase the risk of adverse reactions.
Prevention or Management | Avoid concomitant use of VORANIGO with strong and moderate CYP1A2 inhibitors.
If concomitant use of moderate CYP1A2 inhibitors cannot be avoided, monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended .
Moderate CYP1A2 Inducers
Clinical Impact | Concomitant use of VORANIGO with moderate CYP1A2 inducers and smoking tobacco may decrease vorasidenib plasma concentrations , which may reduce the anti-tumor activity of VORANIGO.
Prevention or Management | Avoid concomitant use of VORANIGO with moderate CYP1A2 inducers and smoking tobacco.
Certain CYP3A Substrates
Clinical Impact | Concomitant use of VORANIGO with CYP3A substrates may decrease plasma concentrations of CYP3A substrates .
Prevention or Management | Avoid concomitant use of VORANIGO with CYP3A substrates, where a minimal concentration change may lead to reduced therapeutic effect. …
About this medicine
VORANIGO tablets contain vorasidenib, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. Vorasidenib is present as the hemicitric acid hemihydrate co-crystal. The chemical name of the co-crystal is 6-(6-chloropyridin-2-yl)-N
2,N
4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine, 2-hydroxypropane-1,2,3-tricarboxylic acid, hydrate (2:1:1). It has the following chemical structure:
The molecular formula is C
14
H
13
ClF
6
N
6 •
½ C
6
H
8
O
7•
½H
2
O and the molecular weight is 519.8 g/mol. Vorasidenib hemicitric acid hemihydrate is a white to off-white solid practically insoluble in aqueous solutions between pH 1.2 to 6.8.
VORANIGO is available as a 10 mg and 40 mg strength film-coated tablet for oral administration. The strengths reflect the amount of active ingredient vorasidenib in each tablet. Each tablet core contains the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicified microcrystalline cellulose and sodium lauryl sulfate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 31405fee-55b7-4857-987e-2724ee76be84. Read the full official label on DailyMed.